{"url_path":"/sec/axsm/8-k/2026-06-03/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1579428/0001193125-26-254708-index.html","accession_number":"0001193125-26-254708","cik":"0001579428","ticker":"AXSM","issuer_name":"Axsome Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1579428/0001193125-26-254708-index.html","primary_entity_key":"0001579428","primary_entity_name":"Axsome Therapeutics, Inc."},"word_count":47,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn June 3, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release entitled “Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation.”\n\nThe full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference."}